Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 13, 2016 (10 years ago)

B-Complex W/Methyl B12/Lido W/Pres

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

B-COMPLEX W/METHYL B12/LIDO W/PRES (BENZYL ETOH 2%), B1-100MG, B2-5-PO4-2MG, B3-50MG, B5-2MG, B6-2MG, LIDOCAINE 1%, METHYL B12 1MG/ML, In a) 1ML Vials, b) 5ML Vials, and c) 10ML Vials, MEDAUS PHARMACY

Drug: Lidocaine

Recalling firm
Medaus, Inc.
Origin
AL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1175-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Lidocaine recalls

See all
Class II · Moderate risk

Lidocaine Ointment USP

Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).

Ongoing Wrong potency / content Sun Pharma /Taro D-0848-2026
Class III · Low risk

Lidolog Kit

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Asclemed USA Inc. D-0713-2026

Other recalls by Medaus, Inc.

All 2016 recalls